Elizabeth A Armstrong, MD | |
110 W Sneed St, Centralia, MO 65240-1375 | |
(573) 682-1330 | |
(573) 682-1936 |
Full Name | Elizabeth A Armstrong |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 110 W Sneed St, Centralia, Missouri |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1720063597 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 2004033761 (Missouri) | Primary |
Mailing Address | Practice Location Address |
---|---|
Elizabeth A Armstrong, MD 110 W Sneed St, Centralia, MO 65240-1375 Ph: (573) 682-1330 | Elizabeth A Armstrong, MD 110 W Sneed St, Centralia, MO 65240-1375 Ph: (573) 682-1330 |
News Archive
Patients with psoriasis are nearly twice as likely to have an autoimmune disease as individuals without the condition, suggest study findings.
A court case has revealed that the insurer Fortis, now called Assurant Health, automatically targeted customers diagnosed with HIV for fraud investigations geared toward finding reasons to revoke their coverage, Reuters reports. After a computer algorithm initiated the investigations, "their insurance policies often were canceled on erroneous information, the flimsiest of evidence, or for no good reason at all, according to the court documents and interviews with state and federal investigators."
The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung.
Shortages of prescription drugs are leaving a growing number of patients waiting for life-saving medicines. Federal officials say the number of prescriptions in short supply tripled from 2005 to 2010. Limited supplies of some drugs have sent prices soaring 1,000 times above normal.
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery.
› Verified 6 days ago